American Marconi Wireless News - ANGLE PLC Announces Result of 2025 Annual General Meeting

Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
RBI Data Reveals Divergence in Credit Card Spending and Debit Card Cash Withdrawals

NYSE - LSE

RYCEF	8.01%	17.86	$
RBGPF	0%	75.17	$
CMSD	1.61%	20.48	$
CMSC	2%	20.46	$
BCE	-0.6%	21.49	$
BCC	3.21%	72.57	$
NGG	1.32%	84.26	$
GSK	2.35%	51.54	$
RIO	3.08%	86.39	$
BTI	-1.33%	60.09	$
VOD	0.7%	15.69	$
RELX	-0.37%	40.02	$
BP	0.13%	44.59	$
JRI	2.51%	11.93	$
AZN	1.56%	189.39	$

ANGLE PLC Announces Result of 2025 Annual General Meeting

BOULEVARD 30.06.2025

Result of 2025 Annual General Meeting

Text size:

GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.

Details of the voting will be available on the Company's website in due course.

For further information:

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Berenberg (NOMAD and Broker)

Toby Flaux, Ciaran Walsh, Milo Bonser

+44 (0) 20 3207 7800

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

+44 (0) 203 727 1000

+1 (212) 850 5624

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.

Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on ACCESS Newswire

G.Stevens--AMWN

American Marconi Wireless News - ANGLE PLC Announces Result of 2025 Annual General Meeting

ANGLE PLC Announces Result of 2025 Annual General Meeting

Featured

Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges

InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10

Phoenix Restaurants Offer Thanksgiving Dinner to Go for Pickup

Crowds Gather at San Francisco Park for Elizabeth Holmes Lookalike Tournament